慢性乙型肝炎病毒感染不同阶段的可溶性免疫标记物。

StephenW

Sci Rep. 2019 Oct 1;9(1):14118. doi: 10.1038/s41598-019-50729-5.
Soluble immune markers in the different phases of chronic hepatitis B virus infection.
Wiegand SB1,2, Beggel B3, Wranke A1,2, Aliabadi E1,2, Jaroszewicz J4, Xu CJ1,5, Li Y5,6, Manns MP1, Lengauer T2,7, Wedemeyer H1,2,8, Kraft ARM1,2, Falk CS2,9, Cornberg M10,11,12,13.
Author information

1
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
2
    German Centre for Infection Research (DZIF), partner-site, Hannover, Braunschweig, Germany.
3
    University of Applied Sciences, Kaiserslautern, Germany.
4
    Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland.
5
    Centre for individualized infection medicine (CIIM), Hannover, Germany.
6
    Helmholtz Centre for Infection Research, Braunschweig, Germany.
7
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, Saarland Informatics, Saarbrücken, Germany.
8
    Department of Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany.
9
    Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany.
10
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. [email protected].
11
    German Centre for Infection Research (DZIF), partner-site, Hannover, Braunschweig, Germany. [email protected].
12
    Centre for individualized infection medicine (CIIM), Hannover, Germany. [email protected].
13
    Helmholtz Centre for Infection Research, Braunschweig, Germany. [email protected].

Abstract

Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by immune markers are not considered in this definition. We aimed to study soluble immune markers and their distribution in different phases of chronic HBV infection. In this cross-sectional retrospective study, we investigated a panel of 14 soluble immune markers (SIM) including CXCL10 in 333 patients with chronic HBV infection. In a small cohort of HBeAg positive patients we analyzed SIM before and after HBeAg seroconversion and compared seroconverters to patients with unknown outcome. Significant differences were documented in the levels of several SIM between the four phases of chronic HBV infection. The most pronounced difference among all investigated SIM was observed for CXCL10 concentrations with highest levels in patients with hepatitis. TGF-β and IL-17 revealed different levels between HBeAg negative patients. HBeAg positive patients with HBeAg seroconversion presented higher amounts of IL-12 before seroconversion compared to HBeAg positive patients with unknown follow up. SIM such as CXCL10 but also IL-12, TGF-β and IL-17 may be useful markers to further characterize the phase of chronic HBV infection.

PMID:
    31575964
DOI:
    10.1038/s41598-019-50729-5

Free full text

StephenW

Sci Rep.2019年10月1日; 9（1）：14118。 doi：10.1038 / s41598-019-50729-5。
慢性乙型肝炎病毒感染不同阶段的可溶性免疫标记物。
Wiegand SB1,2，Beggel B3，Wranke A1,2，Aliabadi E1,2，Jaroszewicz J4，Xu CJ1,5，Li Y5,6，Manns MP1，Lengauer T2,7，Wedemeyer H1,2,8，Kraft ARM1,2 ，Falk CS2,9，康伯格M10、11、12、13。
作者信息

1个
    德国汉诺威汉诺威医学院胃肠病学，肝病学和内分泌学系。
2
    德国感染研究中心（DZIF），合作伙伴地点，德国不伦瑞克汉诺威。
3
    应用技术大学，德国凯泽斯劳滕。
4
    西里西亚医科大学传染病与肝病学系，波兰卡托维兹。
5
    德国汉诺威个人感染医学中心（CIIM）。
6
    亥姆霍兹感染研究中心，德国不伦瑞克。
7
    德国萨尔布吕肯市萨尔州信息学研究所马克斯·普朗克信息学研究所计算生物学与应用算法学系。
8
    德国埃森大学附属医院消化内科和肝病科。
9
    德国汉诺威汉诺威医学院移植免疫研究所。
10
    德国汉诺威汉诺威医学院胃肠病学，肝病学和内分泌学系。 [email protected]。
11
    德国感染研究中心（DZIF），合作伙伴地点，德国不伦瑞克汉诺威。 [email protected]。
12
    德国汉诺威个人感染医学中心（CIIM）。 [email protected]。
13
    亥姆霍兹感染研究中心，德国不伦瑞克。 [email protected]。

抽象

慢性乙型肝炎病毒（HBV）感染可能会经历四个不同的连续阶段，这两个阶段由病毒学以及生化标志物定义，并且在预后和需要抗病毒治疗方面有所不同。当前，在该定义中未考虑免疫标记反映的宿主反应。我们旨在研究可溶性免疫标志物及其在慢性HBV感染不同阶段的分布。在这项横断面回顾性研究中，我们调查了333例慢性HBV感染患者的14种可溶性免疫标记（SIM），包括CXCL10。在一小群HBeAg阳性患者中，我们分析了HBeAg血清转化前后的SIM，并将血清转化剂与预后未知的患者进行了比较。慢性HBV感染的四个阶段之间的几个SIM的水平有明显差异。在所有调查的SIM中，对于肝炎患者中最高水平的CXCL10浓度观察到最明显的差异。 TGF-β和IL-17在HBeAg阴性患者之间显示出不同的水平。 HBeAg血清转化的HBeAg阳性患者与未随访的HBeAg阳性患者相比，血清转化前的IL-12含量更高。 SIM（例如CXCL10）以及IL-12，TGF-β和IL-17可能是进一步表征慢性HBV感染阶段的有用标志物。

PMID：
    31575964
DOI：
    10.1038 / s41598-019-50729-5

免费全文

StephenW

https://www.nature.com/articles/s41598-019-50729-5